Returns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio?
The article profiles five biotech/healthcare stocks and cites recent catalysts and upcoming events. Glaukos (GKOS) highlights Epioxa launch and raised 2026 sales guidance ahead of Q2 2026 results July 29, 2026. TG Therapeutics (TGTX) cites BRIUMVI trial updates and Q2 results early August. Corcept (CORT) points to Lifyorli progress and raised guidance. Relay (RLAY) and Nutex Health (NUTX) note Phase 3 and upcoming quarterly results. It lists large post-publication price gains for each.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the timing of upcoming financial results (GKOS July 29 after close; TGTX early August; NUTX second week of August) and how those prints may confirm or revise full-year guidance after substantial run-ups.
Market read
This is a catalyst calendar style roundup with limited new datapoints, but it does provide specific near-term earnings timing for several high-momentum biotech names.
What to watch
No valuation, dilution risk, cash runway, or detailed endpoint quality is discussed; guidance raises and “promising data” can still reverse on later trial/regulatory scrutiny.
Background
The piece lists multiple biotech names and attributes their large gains to product launches, trial progress, and upcoming earnings or regulatory milestones.
Ticker impact
Glaukos says it launched Epioxa in March 2026 and raised 2026 sales guidance in April, with Phase 2 enrollment completed in June.
Volatile reaction expected around the July 29, 2026 after-close results, with guidance changes likely driving follow-through.
The article provides multiple concrete operational catalysts (launch, guidance raise, Phase 2 enrollment) plus a specific upcoming earnings timing window.
TG Therapeutics highlights BRIUMVI Phase 3 topline results in May 2026 and expects Q2 2026 financial results in early August.
Likely continued momentum into the Q2 release, but guidance or commercial metrics could swing the shares given the large prior run.
The text includes specific trial milestones and a concrete earnings timing window, but no new numeric guidance or trial endpoints are provided here.
Corcept points to Lifyorli progress, including strong Q1 2026 results and raised full-year 2026 guidance, plus an EMA approval expectation by end-2026.
Positive bias, with potential volatility if EMA timing or Part A BELLA readouts disappoint later in 2026.
The article cites guidance raises and regulatory expectations but does not provide fresh quantitative details or a near-dated event date.
Nutex Health reports solid quarterly results and flags Q2 2026 results for the second week of August after a very large 52-week surge.
High sensitivity to the Q2 print, with potential for sharp post-earnings moves given the magnitude of the prior run.
The article provides a specific upcoming earnings window and states results were solid, but lacks new numbers in the text.
Relay Therapeutics cites promising data for the Zovegalisib plus atirmociclib triplet and expects an update on Phase 3 ReDiscover-2 enrollment by end-2026.
Moderate upside bias, with price likely to react to any enrollment update cadence and subsequent Phase 3 progress.
The article provides qualitative trial progress and a broad timing window, but no new trial data or near-term dated event.
Market effects
Reinforces risk-on appetite for clinical and commercial-stage biotech, especially ophthalmology and MS/oncology franchises with near-term readouts.
Primarily US-listed biotech sentiment; no explicit cross-region macro driver is provided.
EMA approval expectations for CORT’s Lifyorli could matter for European biotech sentiment, but the article does not provide new regulatory developments.
Counterpoint
The article is largely a promotional roundup of catalysts and large prior price moves, so the incremental edge may be limited versus waiting for the actual earnings/guidance prints.
Key entities
- public_companyGlaukos Corp.
Ophthalmic pharma with Epioxa launch and upcoming Q2 2026 results on July 29, 2026 after the close.
- public_companyTG Therapeutics Inc.
Commercial-stage biotech with BRIUMVI Phase 3 milestones and Q2 2026 results expected in early August.
- public_companyCorcept Therapeutics Inc.
Commercial-stage company with Lifyorli progress, raised 2026 guidance, and EMA approval expected by end-2026.
- public_companyNutex Health Inc.
Healthcare operations firm with solid quarterly results and Q2 2026 results expected in the second week of August.
- public_companyRelay Therapeutics Inc.
Clinical-stage biotech with Zovegalisib triplet data and an expected Phase 3 enrollment update by end-2026.